A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This 5 arm study will assess the efficacy, pharmacokinetics, safety and tolerability of a
DPP-IV inhibitor compared to placebo in patients with type 2 diabetes. Patients will be
randomized to receive DPP-IV(3) at one of 4 doses (of 12.5mg and above), or placebo p.o.
Patients receiving metformin before the study will continue on the same dose of metformin.
The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.